Cases & Deals

  • Home
  • Practices
  • Zhongze Therapeutics announces exclusive license of DGX-001 with Digestome Therapeutics for Greater China

Share

Zhongze Therapeutics announces exclusive license of DGX-001 with Digestome Therapeutics for Greater China

February 2022

Client(s) Zhongze Therapeutics (Cayman) Holding Limited

Jones Day represented Zhongze Therapeutics (Cayman) Holding, Ltd. in an exclusive license and collaboration agreement with Digestome Therapeutics, Inc. to develop, manufacture, and commercialize Digestome's first-in-class oral therapeutic ALT-100 in the Greater China territory.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.